help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology, doi:10.1210/en.2005-1357
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
147/5/2306    most recent
Author Manuscript (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Toshinai, K.
Right arrow Articles by Nakazato, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Toshinai, K.
Right arrow Articles by Nakazato, M.
Endocrinology Vol. 147, No. 5 2306-2314
Copyright © 2006 by The Endocrine Society

Des-Acyl Ghrelin Induces Food Intake by a Mechanism Independent of the Growth Hormone Secretagogue Receptor

Koji Toshinai, Hideki Yamaguchi, Yuxiang Sun, Roy G. Smith, Akihiro Yamanaka, Takeshi Sakurai, Yukari Date, Muhtashan S. Mondal, Takuya Shimbara, Takashi Kawagoe, Noboru Murakami, Mikiya Miyazato, Kenji Kangawa and Masamitsu Nakazato

Department of Internal Medicine (K.T., H.Y., Y.D., M.S.M., T.SH., T.K., M.N.), Miyazaki Medical College, University of Miyazaki, Miyazaki 889-1692, Japan; Department of Veterinary Physiology (N.M.), University of Miyazaki, Miyazaki 889-2151, Japan; Huffington Center on Aging (Y.S., R.G.S.), Baylor College of Medicine, Texas 77030; Department of Pharmacology (A.Y., T.SA.), University of Tsukuba, Ibaraki 305-8575, Japan; and National Cardiovascular Center Research Institute (M.M., K.K.), Osaka 565-8565, Japan

Address all correspondence and requests for reprints to: Masamitsu Nakazato, M.D., Ph.D., Third Department of Internal Medicine, Miyazaki Medical College, Miyazaki University, Kiyotake, Miyazaki 889-1692, Japan. E-mail: nakazato{at}med.miyazaki-u.ac.jp.


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Ghrelin, an acylated peptide produced predominantly in the stomach, stimulates feeding and GH secretion via interactions with the GH secretagogue type 1a receptor (GHS-R1a), the functionally active form of the GHS-R. Ghrelin molecules exist in the stomach and hypothalamus as two major endogenous forms, a form acylated at serine 3 (ghrelin) and a des-acylated form (des-acyl ghrelin). Acylation is indispensable for the binding of ghrelin to the GHS-R1a. Ghrelin enhances feeding via the neuronal pathways of neuropeptide Y and orexin, which act as orexigenic peptides in the hypothalamus. We here studied the effect of des-acyl ghrelin on feeding behavior. Intracerebroventricular (icv) administration of rat des-acyl ghrelin to rats or mice fed ad libitum stimulated feeding during the light phase; neither ip nor icv administration of des-acyl ghrelin to fasting mice suppressed feeding. The icv administration of des-acyl ghrelin induced the expression of Fos, a marker of neuronal activation, in orexin-expressing neurons of the lateral hypothalamic area, but not neuropeptide Y-expressing neurons of the arcuate nucleus. Peripheral administration of des-acyl ghrelin to rats or mice did not affect feeding. Although icv administration of ghrelin did not induce food intake in GHS-R-deficient mice, it did in orexin-deficient mice. In contrast, icv administration of des-acyl ghrelin stimulated feeding in GHS-R-deficient mice, but not orexin-deficient mice. Des-acyl ghrelin increased the intracellular calcium concentrations in isolated orexin neurons. Central des-acyl ghrelin may activate orexin-expressing neurons, perhaps functioning in feeding regulation through interactions with a target protein distinct from the GHS-R.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
GHRELIN IS A 28-amino-acid peptide isolated from human and rat stomach as an endogenous ligand for the GH secretagogue receptor (GHS-R) (1). The GHS-R, a G protein-coupled seven-transmembrane domain receptor, was initially identified as a receptor for small synthetic molecules termed GH secretagogues (GHSs), such as L-692,429, GHRP-6, and MK-0677, all of which act on the pituitary to stimulate GH secretion (2, 3). Two GHS-R subtypes are generated by alternative splicing of a single gene: the full-length type 1a receptor (GHS-R1a) and a carboxyl-terminally truncated form, the GHS-R type 1b (GHS-R1b), that encodes a protein containing transmembrane domain one to five (2, 3). The GHS-R1a is the functionally active, signal transducing form of the GHS-R, whereas the GHS-R1b is devoid of high-affinity ligand binding and signal transduction activity. Ghrelin molecules, predominantly produced by endocrine cells of the gastric oxyntic glands (4, 5), exist in two major molecular forms, ghrelin and des-n-octanoyl ghrelin (des-acyl ghrelin) (6). These two ghrelin molecules are also produced in the rat hypothalamus, as demonstrated by the combination of reverse-phase HPLC (RP-HPLC) with two separate RIAs recognizing ghrelin and des-acyl ghrelin (7, 8). All ghrelin species identified in fish, amphibians, birds, and many mammals possess a unique structural modification of the hydroxyl group of their third residue, which is either serine or threonine, by n-octanoic acid (9). This acylation is essential for the binding of ghrelin to the GHS-R1a (1, 10, 11); thus, the acylated form has been designated as ghrelin in our original description (1). Administration of ghrelin stimulates food intake in humans and rats (12, 13, 14, 15, 16) but does not change feeding behavior in GHS-R-deficient mice (17), suggesting that ghrelin enhances food intake via GHS-R-mediated signaling.

Several recent in vitro studies have demonstrated that radiolabeled ghrelin and des-acyl ghrelin bound to the membranes of PC-3 prostate tumor cells, H9c2 cadiomyocytes and isolated adipocytes, none of which expressed the GHS-R (18, 19, 20). This binding could be displaced by ghrelin, des-acyl ghrelin, and synthetic GHSs. Ghrelin and des-acyl ghrelin exhibit similar GHS-R-independent biological activities, including a cytoprotective effect on cultured cardiomyocytes (18), the inhibition of cell proliferation of breast carcinoma cell lines (19), the reduction of glycerol release from rat epididymal adipocytes (20), an ionotropic effect on guinea pig papillary muscle (21), and the promotion of bone marrow adipogenesis (22). Although the signaling molecules downstream of des-acyl ghrelin remain undefined, des-acyl ghrelin appears to share a subset of biological activities with ghrelin in peripheral tissues through an unidentified receptor or a target protein unique from the GHS-R.

The coordination of the regulation of food intake and energy expenditure occurs in the hypothalamus. Glucoprivic states induced by fasting or treatment with 2-deoxy-D-glucose (2-DG), a selective inhibitor of carbohydrate metabolism, increase feeding through the activation of orexigenic peptides, neuropeptide Y (NPY) and agouti gene-related protein (AgRP) in the arcuate nucleus (23). Secretion of des-acyl ghrelin from the rat hypothalamus increased in glucoprivic states induced by fasting or treatment with 2-DG (7). The axonal terminals of neurons that produce ghrelin and des-acyl ghrelin make direct synaptic contacts with NPY- and orexin-expressing neurons, which participate in hypothalamic feeding regulation (16, 24). Both ghrelin and des-acyl ghrelin may have a direct central action on the control of feeding.

We here investigated the effect of central or peripheral administration of des-acyl ghrelin on food intake in rats and mice and Fos expression, a marker of neuronal activation (25), in neurons that produce the orexigenic hypothalamic peptides, NPY/AgRP, orexin, or melanin-concentrating hormone (MCH). We studied the functional signaling downstream of des-acyl ghrelin using orexin-deficient mice and rats pretreated with antiorexin-A and -B IgGs. We confirmed that des-acyl ghrelin increased the intracellular calcium concentrations in orexin neurons dispersed from the lateral hypothalamic area (LHA) by the calcium-imaging analysis. We demonstrated that des-acyl ghrelin increased feeding by activation of orexin neurons in the LHA. We examined whether des-acyl ghrelin-induced food intake was mediated by the GHS-R pathway using GHS-R-deficient mice. Des-acyl ghrelin appears to regulate feeding via a receptor or target protein independent of the GHS-R.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Animals
We used male Wistar rats (Charles River Japan, Inc., Shiga, Japan), weighing 300–350 g, male C57BL/6 (Charles River Japan, Inc.), weighing 24–28 g, and male ddy mice (Kiwa Laboratory Animals Co., Ltd., Wakayama, Japan), weighing 35–39 g. Orexin-deficient mice (12-wk-old, male) and GHS-R-deficient mice (12-wk-old, male) were generated by targeted mutation of embryonic stem cells as reported (17, 26). All animals were individually housed in plastic cages at a constant room temperature in a 12-h light (0800–2000 h)/12-h dark cycle and given standard laboratory chow and water ad libitum. All procedures were approved by University of Miyazaki Animal Care and Use Committee and were in accordance with the Japanese Physiological Society’s guidelines for animal care. Anesthesia was given as an ip injection of sodium pentobarbital (Abbot Labs., Chicago, IL). Intracerebroventricular (icv) cannulae were implanted into the lateral cerebral ventricles of rats and mice. Proper placement of the cannulae was verified at the end of the experiment by dye administration. Intravenous cannulae were implanted into the rat right jugular vein. Only animals that exhibited progressive weight gain after surgery were used.

Peptide synthesis
Rat ghrelin and des-acyl ghrelin were purchased from Peptide Institute, Inc. (Osaka, Japan). Adequate purification of synthesized peptides was ascertained by RP-HPLC, ion-exchange-HPLC, capillary zone electrophoresis, amino acid sequencing, and mass spectrometry (MALDI-MS). Ghrelin and des-acyl ghrelin were separately eluted, each as single peaks by RP-HPLC performed using a TSK ODS SIL 120A column (4.6 x 150 mm) (Tosho Co., Tokyo, Japan) with a linear gradient of 10–60% acetonitrile (CH3CN) containing 0.1% trifluoroacetic acid (Fig. 1Go).


Figure 1
View larger version (17K):
[in this window]
[in a new window]
  		FIG. 1. RP-HPLC analysis of synthetic rat ghrelin (A) and des-acyl ghrelin (B) used for experimentation. Each peptide (0.3 nmol) was loaded onto a TSK ODS SIL 120A column using a linear gradient of 10–60% CH3CN containing 0.1% trifluoroacetic acid at a rate of 1.0 ml/min for 40 min. Each peptide is eluted as a single peak whose elution position was identical with that of the corresponding synthetic peptide.

 
Fos expression
Ghrelin (200 pmol/10 µl saline), des-acyl ghrelin (200 pmol/10 µl saline), or saline was injected icv into Wistar rats or GHS-R-deficient mice 90 min before transcardial perfusion with fixative containing 4% paraformaldehyde. The brain was sectioned into 20- or 40-µm-thick samples. Fos-specific immunohistochemistry was performed as described (27). Hypothalamic sections from rats and GHS-R-deficient mice were incubated for 2 d with goat anti-Fos antiserum (Santa Cruz Biotechnology, Santa Cruz, CA; dilution 1:1500), then stained using the avidin-biotin complex method (Vectastain Elite ABC kit; Vector Laboratories, Inc., Burlingame, CA). These sections were also stained with either rabbit antiorexin-A (dilution 1:3000) (16, 27) or rabbit anti-MCH (Phoenix Pharmaceuticals, Inc., Belmont, CA; dilution 1:200) antisera. We observed orexin- and MCH-expressing neurons by light microscopy. For immunofluorescence microscopy, we incubated hypothalamic sections of GHS-R-deficient mice with goat anti-Fos antiserum (dilution 1:1500) for 2 d at 4 C, then performed an additional 2 h incubation with Alexa 488-conjugated donkey antigoat IgG antibody (Molecular Probes, Inc., Eugene, OR; dilution 1:400). After washing with PBS (pH 7.4), samples were incubated with a rabbit antiorexin-A antiserum for 2 d at 4 C and Alexa 546-labeled goat antirabbit IgG antibody (Molecular Probes; dilution 1:400) for a final 2 h. Slides were observed on a fluorescence microscope (BH2-RFC; Olympus, Tokyo, Japan).

Food intake
Experiments were performed 1 wk after the implantation of icv or iv cannulae. First, ghrelin or des-acyl ghrelin (each at 200 pmol/10 µl saline) was administered icv at 1000 h to rats fed ad libitum (n = 10 per group). The 1-, 2-, and 4-h food intake amounts were then measured. Second, des-acyl ghrelin (1 nmol/10 µl saline) was administered icv to rats (n = 6 per group) 10 min before the beginning of the dark phase, after which the 30-min food intake was measured. Third, ghrelin (1.5 nmol) or des-acyl ghrelin (1.5 or 5 nmol/100 µl saline) was administered iv to rats at 1000 h through an iv cannula. Fourth, des-acyl ghrelin (1 or 5 nmol/2 µl saline) was administered ip at 1000 h to C57BL/6 mice fed ad libitum (n = 8 per group). Fifth, 3 h after an icv administration of antiorexin-A and -B (each at 0.25 µg/2.5 µl saline), anti-NPY (0.5 µg/5 µl saline), or normal rabbit serum (0.5 µg/5 µl saline) IgGs, ghrelin or des-acyl ghrelin (each at 200 pmol/5 µl saline) was administered at 1200 h to rats (n = 10–12 per group). Sixth, ghrelin or des-acyl ghrelin (each at 200 pmol/2 µl saline) was administered icv at 1000 h to orexin-deficient mice or their wild-type littermates (n = 6–8 per group). Seventh, ghrelin (200 pmol/2 µl saline), des-acyl ghrelin (200 pmol/2 µl saline) or NPY (1 nmol/2 µl saline; Peptide Institute, Inc.) was administered icv at 1000 h to GHS-R-deficient mice or their wild-type littermates (n = 6–8 per group). With the exception of the first and second experiments, 2-h food intake was measured in all tests. Eighth, ghrelin or des-acyl ghrelin (each at 1 nmol/2 µl saline) was administered icv at 1000 h to ddy mice fed ad libitum. Ninth, des-acyl ghrelin (1 nmol/2 µl saline) was administered icv at 1000 h to ddy mice that had fasted for the previous 16 h (n = 8 per group). Tenth, des-acyl ghrelin (1 nmol/50 µl saline) was administered ip at 1000 h to ddy mice that had fasted for the previous 16 h (n = 8 per group). After the injections of ddy mice in the eighth, ninth, and tenth experiments outlined above, we measured 20-min, 1-h, and 2-h food intake. These feeding tests were performed using a cross-over design experiments in which animals were randomized to receive either test substance with a washout period of 3 d between each administration.

Measurement of cytosolic Ca2+ concentration ([Ca2+]i)
The LHA of rat brain was punched out according to the Atlas of the Rat Brain (28). The tissue was washed twice with HEPES and Krebs-Ringer bicarbonate buffer (HKRB) [129 mM NaCl, 5.0 mM NaHCO3, 4.7 mM KCl, 1.2 mM KH2PO4, 1.8 mM CaCl2, 1.2 mM MgSO4, and 10 mM HEPES (pH 7.4)] containing 10 mM glucose. The LHA was incubated in HKRB supplemented with 1 mg/ml papain (Sigma-Aldrich, St. Louis, MO), 5 mg/ml deoxyribonuclease, and 0.025% BSA for 20 min at 36 C in a shaking water bath, then LHA cells were dispersed by mechanical desegregation for 4 min. The cell suspension was diluted with HKRB and centrifuged at 100 x g for 5 min. The pellet was resuspended in HKRB and distributed onto the glass well (Nunc 96 Microwell Optical Bottom Plate; Nalge Nunc International, Rochester, NY). Measurement of [Ca2+]i was carried out 2–4 h after the preparation of cells. The cells were loaded with Fluo-3 for 20 min in HEPES buffer solution [10 mM HEPES, 140 mM NaCl, 5.0 mM KCl, 1.2 mM MgCl2, 2.0 mM CaCl2, 10 mM glucose, and 2 µm Fluo-3/acetoxymethylester (Dojindo Labs, Kumamoto, Japan) (pH 7.2)]. They were washed twice with HEPES buffer, then filled with 100 µl HEPES buffer. One min after, 50 µl of 3 µM rat des-acyl ghrelin were added into the well. [Ca2+]i was determined by measuring fluorescence signal from the Ca2+ indicator Fluo-3/acetoxymethylester, with 480 nm excitation and 530 nm emission using a cooled charge-coupled device camera, and the ratio image was produced in Functional Imaging Cell-Sorting System (IMACS; Hamamatsu Photonics, Hamamatsu, Japan). The level of [Ca2+]i in a single neuron was recorded for 6 min after the administration of des-acyl ghrelin. After [Ca2+]i measurement, the neurons were fixed with 4% paraformaldehyde overnight. They were incubated with rabbit antiorexin-A antiserum (dilution 1:1500) for 2 d at 4 C, then Alexa 350-conjugated goat antirabbit IgG antibody (dilution 1:400) for 2 h (16, 27). The picture of calcium imaging was collated with the immunohistochemical picture. Fluorescence signals from Fluo-3 were converted automatically to pseudo colors in IMACS. The levels of [Ca2+]i were assigned pseudo colors ranging from blue of the lowest value through yellow to red of the highest value. Fluorescence signals from Alexa-350 were shown in white.

Measurement of locomotor activity
Locomotor activity of rats was measured using a rat locomotor activity recording system (Muromachi Co. Ltd., Tokyo, Japan) comprising infrared sensors, an interface and a computer. The infrared sensors were placed above the cages and measured all locomotor activity. A cage with the infrared sensor was placed in an isolated chamber with a controlled light/dark cycle. Rats were given icv des-acyl ghrelin (1 nmol/10 µl saline), human orexin-A (Peptide Institute, Inc.; 1 nmol/10 µl saline) or saline administration icv at 0900 h (n = 5 per group), then these rats were immediately returned to their individual cages. Locomotor activity counts were made 30 min and analyzed by Compact ACTAM Software (Muromachi Co. Ltd.).

GH response
Ghrelin or des-acyl ghrelin (each at 1.5 nmol/100 µl) was administered iv to rats (n = 6 per group) at 1000 h. Blood samples (80 µl) were obtained from the tail veins at 0, 15, 30, and 60 min after administration. After removal, six anterior pituitary glands of rats were immersed in Hanks’ balanced salt solution, then incubated at 37 C for 30 min. Each one pituitary grand was placed in a polystyrene well (16 mm in diameter; Iwaki Glassware Co., Tokyo, Japan) filled with oxygenated medium (DMEM containing 2.5% fetal calf serum and 2.5% bovine serum). After rinsing twice in 500 µl medium for 1 min each, 750 µl medium was added into each well for 5 min. The medium was then collected into plastic microtubes to evaluate basal GH secretion. The pituitary glands were then stimulated for 5 min with medium containing either ghrelin or des-acyl ghrelin (1 µM). The medium was collected into plastic microtubes to quantify GH concentration with a Biotrak Rat GH RIA kit (Amersham, Buckinghamshire, UK). The experiment was concluded by treatment with 60 mM KCl to induce depolarization.

Statistic analysis
Data (mean ± SEM) were analyzed by ANOVA and the post hoc Scheffé’s F test. Differences were considered to be significant when the P values were less than 0.05.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
Des-acyl ghrelin-induced food intake
The icv administration of either ghrelin or des-acyl ghrelin to rats stimulated food intake (Fig. 2AGo). Although ghrelin increased food intake for at least 2 h after administration, the effect of des-acyl ghrelin lasted for only 1 h. Des-acyl ghrelin also significantly increased the early dark-phase food intake in rats in comparison to saline administration (des-acyl ghrelin, 2.04 ± 0.37 g/30 min; saline, 0.96 ± 0.23 g/30 min, P < 0.05). Next, we studied the effect of peripherally administered des-acyl ghrelin on feeding. A single iv administration of ghrelin significantly increased feeding, whereas des-acyl ghrelin did not (Fig. 2BGo). An ip administration of des-acyl ghrelin to C57BL/6 mice fed ad libitum did not increase food intake (des-acyl ghrelin 1 nmol, 0.05 ± 0.03 g/2 h; 5 nmol, 0.04 ± 0.02 g/2 h; saline, 0.05 ± 0.02 g/2 h).


Figure 2
View larger version (19K):
[in this window]
[in a new window]
  		FIG. 2. Effect of ghrelin or des-acyl ghrelin on food intake in rats. A, Intracerebroventricular administration of des-acyl ghrelin or ghrelin (each at 200 pmol) at 1000 h. *, P < 0.001 vs. saline; #, P < 0.05; ##, P < 0.001 vs. ghrelin; §, P < 0.001 vs. 1-h food intake. B, Intravenous administration of ghrelin (1.5 nmol) or des-acyl ghrelin (1.5 or 5 nmol) at 1000 h. *, P < 0.001 vs. saline; #, P < 0.001 vs. ghrelin.

 
Fos expression
Intracerebroventricular administration of ghrelin induced Fos expression in the LHA and arcuate nucleus (Fig. 3AGo). In contrast, icv administration of des-acyl ghrelin induced Fos in the LHA, but not the arcuate nucleus or the paraventricular nucleus (PVN) (Fig. 3Go, D–G). By double immunohistochemistry, ghrelin induced Fos in 32 ± 7% of orexin-immunoreactive neurons (Fig. 3BGo). Des-acyl ghrelin induced Fos in 22 ± 5% of orexin-immunoreactive neurons (Fig. 3HGo). In the LHA, neither ghrelin nor des-acyl ghrelin induced Fos in MCH-immunoreactive neurons (Fig. 3Go, C and I). Intracerebroventricular administration of des-acyl ghrelin to GHS-R-deficient mice induced Fos in the LHA, but not the arcuate nucleus (Fig. 3Go, J and K). In GHS-R-deficient mice, des-acyl ghrelin induced Fos expression in 28 ± 2% of orexin-immunoreactive neurons, whereas ghrelin did not induce the expression of Fos in any hypothalamic neurons (Fig. 3LGo).


Figure 3
View larger version (138K):
[in this window]
[in a new window]
  		FIG. 3. Fos expression in the hypothalamus after icv administration of ghrelin or des-acyl ghrelin (each at 200 pmol). A, Fos expression (dark blue-black) in the LHA and arcuate nucleus of rats given ghrelin. B, Costaining (arrows) of Fos (dark blue-black) and orexin (brown) in rats given ghrelin. The inset is a higher magnification of Fos expression in an orexin-expressing neuron. C, No Fos (dark blue-black) expression in MCH-expressing neurons (brown) after ghrelin administration. D, Fos expression (dark blue-black) in the hypothalamus of rats given des-acyl ghrelin. E, Fos expression (dark blue-black) in the LHA of rats given des-acyl ghrelin. No Fos (dark blue-black) expression in the arcuate nucleus (F) or the PVN (G) after des-acyl ghrelin administration. H, Costaining (arrows) of Fos (dark blue-black) and orexin (brown) in rats given des-acyl ghrelin. The inset is a higher magnification of Fos expression in an orexin-expressing neuron. I, No expression of Fos (dark blue-black) is observed in MCH-expressing neurons (brown) after des-acyl ghrelin administration. J, Fos expression (dark blue-black) in the LHA of GHS-R-deficient mice given des-acyl ghrelin. K, No Fos expression (brown) in the arcuate nucleus of GHS-R-deficient mice given des-acyl ghrelin. L, Costaining of Fos (green) and orexin (red) in the LHA neurons of GHS-R-deficient mice given des-acyl ghrelin. 3V, Third ventricle; Arc, arcuate nucleus; f, fornix. Scale bars, A, D, 200 µm; B, C, E, F, H, G, H, I, J, K, L, 50 µm.

 
Functional relationship between des-acyl ghrelin and orexin in feeding
We examined the effects of orexin and NPY blockades on des-acyl ghrelin-induced food intake. Both ghrelin and des-acyl ghrelin increased food intake in rats given an icv administration of control IgG (Fig. 4Go). Pretreatment with antiorexin-A and -B IgGs, however, reduced ghrelin-induced food intake by 29% from the amounts seen in rats given control IgG and ghrelin, whereas pretreatment with antiorexin-A and -B IgGs completely abolished des-acyl ghrelin-induced food intake. Whereas pretreatment with anti-NPY IgG reduced ghrelin-induced feeding in rats in comparison to rats given control IgG and ghrelin, anti-NPY IgG did not affect des-acyl ghrelin-induced feeding in comparison to rats given control IgG and des-acyl ghrelin (Fig. 4Go).


Figure 4
View larger version (29K):
[in this window]
[in a new window]
  		FIG. 4. The effect of antiorexin-A and -B (each at 0.25 µg) and anti-NPY (0.5 µg) IgGs on ghrelin- or des-acyl ghrelin-induced feeding. Ghrelin or des-acyl ghrelin (each at 200 pmol) was given to rats 3 h after icv administration of IgG. The 2-h food intake was then measured. NRS, Normal rabbit serum. *, P < 0.01 vs. ghrelin; #, P < 0.05; ##, P < 0.01 vs. NRS IgG.

 
Orexin-deficient mice were used to verify the functional relationship between des-acyl ghrelin and orexin in feeding regulation. Although ghrelin induced food intake in orexin-deficient mice, the potency of this induction in these mice was significantly reduced from that seen in wild-type littermates (Fig. 5AGo). Des-acyl ghrelin stimulated feeding in wild-type mice, but not in orexin-deficient mice (Fig. 5AGo). To investigate whether des-acyl ghrelin regulates feeding through the GHS-R, we gave an icv administration of des-acyl ghrelin to GHS-R-deficient mice. Des-acyl ghrelin, but not ghrelin, stimulated feeding in GHS-R-deficient mice (Fig. 5BGo). Des-acyl ghrelin-induced feeding in GHS-R-deficient mice was more potent than that induced in wild-type littermates. NPY was used as a positive control to evaluate the orexigenic effects on GHS-R-deficient mice. NPY-induced food intake was similar in both GHS-R-deficient mice and their wild-type littermates (Fig. 5BGo).


Figure 5
View larger version (21K):
[in this window]
[in a new window]
  		FIG. 5. A, Effect of icv administration of ghrelin or des-acyl ghrelin (each at 200 pmol) on 2-h food intake in orexin-deficient mice. *, P < 0.05, **; P < 0.01 vs. saline; #, P < 0.05; ##, P < 0.01 vs. ghrelin, §, P < 0.05, §§, P < 0.01 vs. wild-type mice. B, Effect of icv administration of ghrelin (200 pmol), des-acyl ghrelin (200 pmol), or NPY (1 nmol) on 2-h food intake in GHS-R-deficient mice. *, P < 0.05; **, P < 0.001 vs. saline; #, P < 0.001 vs. ghrelin; §, P < 0.05; §§, P < 0.01 vs. wild-type mice.

 
Intracerebroventricular administration of des-acyl ghrelin increased food intake in ddy mice fed ad libitum (Fig. 6AGo). Neither icv nor ip administration of des-acyl ghrelin suppressed food intake in ddy mice that had fasted for 16 h (Fig. 6Go, B and C).


Figure 6
View larger version (18K):
[in this window]
[in a new window]
  		FIG. 6. Effect of des-acyl ghrelin on food intake in ddy mice. A, Intracerebroventricular administration of ghrelin or des-acyl ghrelin (each at 1 nmol) at 1000 h to mice ad libitum. *, P < 0.05; **, P < 0.01; ***, P < 0.001 vs. saline; #, P < 0.01 vs. ghrelin. Neither icv (B) nor ip (C) administration of des-acyl ghrelin (1 nmol) suppressed feeding in mice that had fasted for 16 h.

 
Cytosolic [Ca2+]i response in orexin neurons
We studied the cytosolic [Ca2+]i response of orexin-expressing neurons to des-acyl ghrelin. Some cells dispersed from the rat LHA showed increased cytosolic [Ca2+]i in response to des-acyl ghrelin administration (Fig. 7Go, A and B). These cells showed orexin immunoreactivity by immunohistochemistry (Fig. 7CGo).


Figure 7
View larger version (40K):
[in this window]
[in a new window]
  		FIG. 7. Effect of des-acyl ghrelin on [Ca2+]i response in isolated orexin-expressing neurons. A, A picture shows the basal level of [Ca2+]i in neurons (blue) before administration of des-acyl ghrelin. B, Des-acyl ghrelin increased cytosolic [Ca2+]i in two neurons (arrows). C, Immunostaining of orexin-expressing neurons (white) after the measurement of [Ca2+]i response.

 
Locomotor activity
We examined the effect of des-acyl ghrelin on locomotor activity. Intracerebroventricular administration of des-acyl ghrelin to rats significantly increased locomotor activity compared with saline administration (Fig. 8Go). Orexin-A also significantly increased locomotor activity in these rats.


Figure 8
View larger version (23K):
[in this window]
[in a new window]
  		FIG. 8. Effects of icv administration of des-acyl ghrelin or orexin-A (each at 1 nmol) on locomotor activity in rats. *, P < 0.05 vs. saline.

 
GH response
We studied the release of GH in response to peripheral des-acyl ghrelin administration. Intravenous administration of ghrelin elicited a marked increase in plasma GH levels, with the peak occurring 15 min after administration (Fig. 9AGo). Intravenous administration of des-acyl ghrelin did not stimulate GH release. We examined the effect of des-acyl ghrelin on GH release from isolated samples of the rat anterior pituitary. GH concentrations in the culture medium of the anterior pituitary cultures increased in response to ghrelin administration, but not to des-acyl ghrelin administration (Fig. 9BGo).


Figure 9
View larger version (15K):
[in this window]
[in a new window]
  		FIG. 9. A, Effect of iv administration of ghrelin or des-acyl ghrelin (each at 1.5 nmol) on the plasma GH concentration in rats. *, P < 0.001 vs. preadministration; #, P < 0.001 vs. ghrelin at the same time point. B, Effect of ghrelin or des-acyl ghrelin administration (each at 200 pmol) on GH release from rat pituitary gland (n = 6 per group). *, P < 0.001 vs. control vehicle.

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
At present, the amino acid sequences of ghrelin peptides in 21 species of fish, amphibians, birds, and mammals have been determined (9). All of the ghrelin molecules identified possess a serine or threonine as the third amino acid residue. A hydroxyl group of this amino acid forms an ester with a monocarboxylic acid of medium-chain fatty acid (6). Ghrelin peptide is present in the stomach of humans, rats, and mice as two major molecular forms: ghrelin and des-acyl ghrelin (6). In the plasma, ghrelin accounts for only 2–20% of total ghrelin immunoreactivity (6, 7, 28, 29, 30). This is likely due to the shorter half-life of ghrelin than that of des-acyl ghrelin because plasma ghrelin rapidly disappears from the circulation because of binding to the GHS-R in the systemic tissues (31). Deacylation of ghrelin to des-acyl ghrelin, which rapidly occurs in the plasma, is also responsible for the reduced half-life of ghrelin. Two enzymes involved in the deacylation of ghrelin have been identified: high-density lipoprotein-associated paraoxonase functions in the plasma, whereas lysophospholipase I, a thioesterase active against palmitoyl-Gs{alpha} and plamitoyl-coenzyme A, functions in the stomach (32, 33, 34). In contrast, the enzyme that catalyzes the acyl modification of ghrelin has not been identified.

Acylation of ghrelin is essential for ghrelin’s GH-releasing activity (1, 9, 10); several recent in vitro studies have shown that des-acyl ghrelin exhibits biological activities on the cell proliferation and metabolism of cardiomyocytes, adipocytes, myocytes, and myelocytes (18, 19, 20, 21, 22). Although many of these cells did not express the GHS-R, des-acyl ghrelin bound to their cell membranes (18, 19, 20). We here examined the orexigenic activity of des-acyl ghrelin. We confirmed the purity of ghrelin and des-acyl ghrelin by several biochemical methods before using these substances in feeding experiments. Both ghrelin and des-acyl ghrelin were completely pure by RP-HPLC, ion-exchange-HPLC, capillary zone electrophoresis, and mass spectrometry. Des-acyl ghrelin did not stimulate GH release when either peripherally administered to rats or applied directly to the rat pituitary in vitro. Intracerebroventricular administration of des-acyl ghrelin significantly induced feeding during both the light and dark phases in rats. Intracerebroventricular administration of des-acyl ghrelin also increased food intake in GHS-R-deficient mice and their wild-type littermates. Two recent studies reported the anorexic activity of des-acyl ghrelin in rats and mice (35, 36). In these studies, ip administration of des-acyl ghrelin suppressed feeding in rats had fasted for 16 h (35). Both ip and icv administrations of des-acyl ghrelin suppressed feeding in ddy mice that had been fasting for 16 h; icv administration of des-acyl ghrelin did not significantly change the light phase food intake in ddy mice fed ad libitum (36). These studies described that icv and ip administrations of des-acyl ghrelin expressed Fos in the PVN neurons, presumably corticotropin-releasing factor (CRF) neurons (35, 36). We also examined the effect of des-acyl ghrelin on feeding in ddy mice because the anorexic effect noted above contrasted the orexigenic effect observed in C57BL/6 mice. An icv administration of des-acyl ghrelin significantly increased the light phase food intake of ddy mice fed ad libitum. The icv administration of des-acyl ghrelin did not suppress food intake in ddy mice that had fasted for 16 h. In addition, an icv administration of des-acyl ghrelin did not express Fos in any neurons of the PVN where CRF-producing neurons are present. Because the effects of peptides in feeding experiments are hampered by unsatisfactory habituation (37, 38), all of the rats and mice used in these experiments were satisfactorily acclimated to handling before ip and icv injections. We do not know why our findings conflicted with previous results; des-acyl ghrelin, however, reproducibly stimulated feeding in rats, C57BL/6 mice and ddy mice. Des-acyl ghrelin, which was synthesized in the rat hypothalamus, was released in response to fasting (7). The ratio of des-acyl ghrelin to ghrelin in the rat hypothalamus was 2:1 under ad libitum conditions, and this ratio did not change in upon fasting. Des-acyl ghrelin, as well as ghrelin, may serve as orexigenic peptides in the hypothalamus.

Ghrelin-producing neurons localize to the hypothalamic arcuate nucleus and adjacent to the third ventricle between the dorsal, ventral, paraventricular, and arcuate hypothalamic nuclei of rats and mice (1, 24). Ghrelin fibers synapse on NPY/AgRP neurons in the arcuate nucleus and orexin neurons in the LHA (16, 24, 39). We investigated the signaling events downstream of des-acyl ghrelin that stimulates feeding. Fos expression, induced by icv administration of des-acyl ghrelin, was restricted to orexin-expressing neurons in the LHA. Des-acyl ghrelin-induced food intake was completely abolished in rats by pretreatment with antiorexin IgG, but not anti-NPY IgG or control serum IgG. Des-acyl ghrelin did not stimulate feeding in orexin-deficient mice. These results indicate that des-acyl ghrelin-induced feeding is mediated by the activation of the orexin pathway. Orexin-A and -B are hypothalamic peptides functioning in the regulation of feeding, energy homeostasis, and arousal (40). Approximately 3000 orexin-expressing neurons are present in the LHA of rats and mice. Orexin-positive nerve fibers have wide projections onto a variety of brain regions, such as the arousal centers in the forebrain and brain stem and the feeding center within the hypothalamus (40). Orexin-expressing neurons are heterogeneous in their anatomical projections and physiological functions, playing multifaceted roles in the brain. Ghrelin fibers project to orexin-positive neurons (16) and ghrelin stimulated elecrophysiological activity of isolated orexin neurons in the whole-cell patch-clamp study (41); we demonstrate here that ghrelin and des-acyl ghrelin acted on orexin-expressing neurons and that des-acyl ghrelin increased intracellular calcium concentration in isolated orexin neurons. There are three possible subtypes of orexin neurons: those that express the GHS-R as a receptor for ghrelin, those expressing an as-yet unknown target protein of des-acyl ghrelin, neurons possessing both proteins. Orexin also functions to maintain wakefulness (40). We examined the effect of des-acyl ghrelin on locomotor activity. As expected, icv administration of des-acyl ghrelin increased locomotor activity, suggesting that des-acyl ghrelin may increase wakefulness and locomotor activity for food seeking by stimulating orexin neurons.

We next investigated the functional relationship between des-acyl ghrelin and the GHS-R using GHS-R-deficient mice. The icv administration of des-acyl ghrelin to GHS-R-deficient mice induced food intake and Fos expression in orexin-expressing neurons. The icv administration of ghrelin to GHS-R-deficient mice did not stimulate food intake. Des-acyl ghrelin did not bind to GHS-R-expressing Chinese hamster ovary cells and did not inhibit the binding of ghrelin to rat pituitary culture cells expressing the GHS-R (1, 10, 42), implying that des-acyl ghrelin does not compete with ghrelin for the binding to the GHS-R. Thus, des-acyl ghrelin is thought to stimulate feeding via a mechanism independent of the GHS-R.

A number of gastrointestinal peptides transmit satiety or starvation signals to the nucleus of the solitary tract via the vagal afferents and/or to the hypothalamus via the bloodstream (43). Although iv administration of ghrelin stimulated both vagal afferents and feeding, iv administration of des-acyl ghrelin affected neither (44). Peripheral administration of des-acyl ghrelin to rats and mice did not affect feeding. Receptors on vagal afferents are generated by nodose ganglion neurons, transported to the nerve terminals through axonal transport (45). These results indicate that a receptor or a target protein binding to des-acyl ghrelin is not expressed in nodose ganglion neurons. The plasma concentration of des-acyl ghrelin increased upon fasting (7). The peripheral des-acyl ghrelin does not act to suppress feeding.

In summary, centrally administered des-acyl ghrelin increased feeding through activation of the orexin pathway. In addition to its peripheral actions, which include cell proliferation, inhibition of apoptosis, and fat metabolism (18, 19, 20, 21, 22), des-acyl ghrelin may function in hypothalamic feeding regulation. Central administration of des-acyl ghrelin to GHS-R-deficient mice stimulated feeding, suggesting that des-acyl ghrelin acts on a target protein that is specific for des-acyl ghrelin and independent of the GHS-R. Ghrelin and des-acyl ghrelin act in the regulations of peripheral cell functions through a common putative target protein (18, 19, 20, 21, 22). Ghrelin and des-acyl ghrelin function as orexigenic peptides in the hypothalamus. Des-acyl ghrelin may have basal effects of ghrelin-related peptides. Further studies examining the physiological and neuroanatomical interactions between des-acyl ghrelin and its target will establish roles of ghrelin peptides in the regulation of feeding and energy homeostasis.


   Acknowledgments
 
We thank Tomoko Tsuruta, Etsuko Masuda, and Ryusuke Koshida for assistance.


   Footnotes
 
This study was supported in part by grants from 21st Century Center of Excellence Program and grants-in-aid from the Ministry of Education, Culture, Sports, Science and Technology; the Ministry of Health, Labor, and Welfare; Novartis Foundation for Gerontological Research; Society of Molecular Mechanism of Digestive Tract; The Fujisawa Foundation; and Takeda Medical Research Foundation.

Disclosure summary: all authors have nothing to declare.

First Published Online February 16, 2006

Abbreviations: AgRP, Agouti gene-related protein; CRF, corticotropin-releasing factor; 2-DG, 2-deoxy-D-glucose; GHS, GH secretagogue; GHS-R, GH secretagogue receptor; HKRB, Krebs-Ringer bicarbonate buffer; icv, intracerebroventricular(ly); LHA, lateral hypothalamic area; MCH, melanin-concentrating hormone; NPY, neuropeptide Y; PVN, paraventricular nucleus; RP-HPLC, reverse-phase HPLC.

Received October 25, 2005.

Accepted for publication February 9, 2006.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K 1999 Ghrelin is a novel growth hormone releasing acylated peptide from stomach. Nature 402:656–660[CrossRef][Medline]
  2. Howard AD, Feighner SD, Cully DF, Arena JP, Liberator PA, Rosenblum CI, Hamelin M, Hreniuk DL, Palyha OC, Anderson J, Paress PS, Diaz C, Chou M, Liu KK, McKee KK, Pong SS, Chaung LY, Elbrecht A, Dashkevicz M, Heavens R, Rigby M, Sirinathsinghji DJS, Dean DC, Melillo DG, Patchett AA, Nargund R, Griffin PR, Demartino JA, Gupta SK, Schaeffer JM, Smith RG, Van der Ploeg LHT 1996 A receptor in pituitary and hypothalamus that functions in growth hormone rrelease. Science 273:974–977[Abstract]
  3. MaKee KK, Palyha OC, Feighner SD, Hreniuk DL, Tan CP, Phillips MS, Smith RG, Van der Ploeg LHT, Howard AD 1997 Molecular analysis of rat pituitary and hypothalamus growth hormone secretagogue receptors. Mol Endocrinol 11:415–423[Abstract/Free Full Text]
  4. Date Y, Kojima M, Hosoda H, Sawaguchi A, Mondal MS, Suganuma T, Matsukura S, Kangawa K, Nakazato M 2000 Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans. Endocrinology 141:4255–4261[Abstract/Free Full Text]
  5. Dornonville de la Cour C, Björkqvist M, Sandvik AK, Bakke I, Zhao CM, Chen D, Håkanson R 2001 A-like cells in the rat stomach contain ghrelin and do not operate under gastrin control. Regul Pept 99:141–150[CrossRef][Medline]
  6. Hosoda H, Kojima M, Matsuo H, Kangawa K 2000 Ghrelin and des-acyl ghrelin: two major forms of rat ghrelin peptide in gastrointestinal tissue. Biochem Biophys Res Commun 281:1220–1225
  7. Sato T, Fukue Y, Teranishi H, Yoshida Y, Kojima M 2005 Molecular forms of hypothalamic ghrelin and its regulation by fasting and 2-deoxy-D-glucose administration. Endocrinology 146:2510–2516[Abstract/Free Full Text]
  8. Mondal MS, Date Y, Yamaguchi H, Toshinai K, Tsuruta T, Kangawa K, Nakazato M 2005 Identification of ghrelin and its receptor in neurons of the rat arcuate nucleus. Regul Pept 126:55–59[CrossRef][Medline]
  9. Kojima M, Kangawa K 2005 Ghrelin: Structure and function. Physiol Rev 85:495–522[Abstract/Free Full Text]
  10. Muccioli G, Tschöp M, Papotti M, Deghenghi R, Heiman M, Ghigo E 2002 Neuroendocrine and peripheral activities of ghrelin: implication in metabolism and obesity. Eur J Pharmacol 440:235–254[CrossRef][Medline]
  11. Matsumoto M, Hosoda H, Kitajima Y, Morozumi N. Minamitake Y, Tanaka S, Matsuo H, Kojima M, Hayashi Y, Kangawa K 2001 Structure-activity relationship of ghrelin: pharmacological study of ghrelin peptides. Biochem Biophys Res Commun 287:142–146[CrossRef][Medline]
  12. Nakazato M, Murakami N, Date Y, Kojima M, Matsuo H, Kangawa K, Matsukura S 2001 A role for ghrelin in the central regulation of feeding. Nature 409:194–198[CrossRef][Medline]
  13. Shintani M, Ogawa Y, Ebihara K, Aizawa-Abe M, Miyanaga F, Takaya K, Hayashi, T, Inoue G, Hosoda K, Kojima M, Kangawa K, Nakao K 2001 Ghrelin, an endogenous growth hormone secretagogue, is a novel orexigenic peptide that antagonizes leptin action through the activation of hypothalamic neuropeptide Y/Y1 receptor pathway. Diabetes 50:227–232[Abstract/Free Full Text]
  14. Kamegai J, Tamura H, Shimizu T, Ishii S, Sugihara H, Wakabayashi I 2001 Chronic central infusion of ghrelin increases hypothalamic neuropeptide Y and Agouti-related protein mRNA levels and body weight in rats. Diabetes 50:2438–2443[Abstract/Free Full Text]
  15. Bagnasco M, Tulipano G, Melis MR, Argiolas A, Cocchi D, Muller EE 2003 Endogenous ghrelin is an orexigenic peptide acting in the arcuate nucleus in response to fasting. Regul Pept 111:161–167[CrossRef][Medline]
  16. Toshinai K, Date Y, Murakami N, Shimada M, Mondal MS, Shimbara T, Guan LL, Wand QP, Funahashi H, Sakurai T, Shioda S, Matsukura S, Kanagawa K, Nakazato M 2003 Ghrelin-induced food intake is mediated via the orexin pathway. Endocrinology 144:1506–1512[Abstract/Free Full Text]
  17. Sun Y, Wang P, Zheng H, Smith RG 2003 Ghrelin stimulation of growth hormone release and appetite is mediated through the growth hormone secretagogue receptor. Proc Natl Acad Sci USA 101:4679–4684
  18. Baldanzi G, Filigheddu N, Cutrupi S, Catapano F, Bonissoni S, Fubini A, Malan D, Baj G, Granata R, Broglio F, Papotti M, Surico N, Bussolino F, Isgaard J, Deghenghi R, Sinigaglia F, Prat M, Muccioli G, Ghigo E, Graziani A 2004 Ghrelin and de-acyl ghrelin inhibit cell death in cardiomyocytes and endothelial cells through ERK1/2 and PI 3-kinase/AKT. J Cell Biol 159:1029–1037
  19. Cassoni P, Ghe C, Marrocco T, Tarabra E, Allia E, Catapano F, Deghenghi R, Ghigo E, Papotti M, Muccioli G 2004 Expression of ghrelin and biological activity of specific receptors for ghrelin and des-acyl ghrelin in human prostate neoplasms and related cell line. Eur J Endocrinol 150:173–184[Abstract]
  20. Muccioli G, Pons N, Ghe C, Catapano F, Granata R, Ghigo E 2004 Ghrelin and des-acyl ghrelin both inhibit isoproterenol-induced lipolysis in rat adipocytes via a non-type 1a growth hormone secretagogue receptor. Eur J Pharmacol 498:27–35[CrossRef][Medline]
  21. Bedendi I, Allatti G, Marcantoni A, Malan D, Catapano F, Ghe C, Deghenghi R, Ghigo E, and Muccioli G 2003 Cardiac effects of ghrelin and its endogenous derivatives des-octanoyl ghrelin and des-Gln14-ghrelin. Eur J Pharmacol 476:87–95[CrossRef][Medline]
  22. Thompson NM, Gill DAS, Davies R, Loveridge N, Houston PA, Robinson ICAF, Wells T 2004 Ghrelin and des-octanoyl ghrelin promote adipogenesis directly in vivo by a mechanism independent of the type 1a growth hormone secretagogue receptor. Endocrinology 145:234–242[Abstract/Free Full Text]
  23. Fraley GS, Ritter S 2003 Immunolesion of norepinephrine and epinephrine afferents to medial hypothalamus alters basal and 2-deoxy-D-glucose-induced neuropeptide Y and agouti gene-related protein messenger ribonucleic acid expression in the arcuate nucleus. Endocrinology 144:75–83[Abstract/Free Full Text]
  24. Cowley MA, Smith RG, Diano S, Tschöp M, Pronchuk N, Grove KL, Strasburger CJ, Bidlingmaier M, Esterman M, Heiman ML, Garcia-Segura LM, Nillni EA, Mendez P, Low MJ, Sotonyi P, Friedman JM, Liu H, Pinto S, Colmers WF, Cone RD, Horvath TL 2003 The distribution and mechanism of action of ghrelin in the CNS demonstrates a novel hypothalamic circuit regulating energy homeostasis. Neuron 37:649–661[CrossRef][Medline]
  25. Sagar SM, Sharp FR, Curran T 1988 Expression of c-fos protein in brain: metabolic mapping at the cellular level. Science 240:1328–1331[Abstract/Free Full Text]
  26. Chemelli RM, Willie JT, Sinton CM, Elmquist JK, Scammell T, Lee C, Richardson JA, Williams SC, Xiong Y, Kisanuki Y, Fitch TE, Nakazato M, Hammer RE, Saper CB, Yanagisawa M 1999 Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 98:437–451[CrossRef][Medline]
  27. Date Y, Ueta Y, Yamashita H, Yamaguchi H, Matsukura S, Kangawa K, Sakurai T, Yanagisawa M, Nakazato M 1999 Orexins, orexigenic hypothalamic peptides, interact with autonomic, neuroendocrine and neuroregulatory systems. Proc Natl Acad Sci USA 96:748–753[Abstract/Free Full Text]
  28. Paxinos G, Watson C 1998 The rat brain in stereotaxic coordinates. 4th ed. San Diego: Academic Press
  29. Nishi Y, Hiejima H, Hirohara M, Sato T, Kangawa K, Kojima M 2005 Developmental changes in the pattern of ghrelin’s acyl modification and the levels of acyl-modified ghrelin in murine stomach. Endocrinology 146:2709–2715[Abstract/Free Full Text]
  30. Akamizu T, Shinomiya T, Irako T, Fukunaga M, Nakai Y, Nakai Y, Kangawa K 2005 Separate measurement of plasma levels of acylated and desacyl ghrelin in healthy subjects using a new direct ELISA assay. J Clin Endocrinol Metab 90:6–9[Abstract/Free Full Text]
  31. Akamizu T, Takaya K, Irako T, Hosoda H, Teramukai S, Matsuyama A, Tada H, Miura K, Shimizu A, Fukushima M, Yokode M, Tanaka K, Kangawa K 2004 Pharmacokinetics, safety, and endocrine and appetite effects of ghrelin administration in young healthy subjects. Eur J Endocrinol 150:447–455[Abstract]
  32. Beaumont NJ, Skinner VO, Tan TM, Ramesh BS, Byrne DJ, MacColl GS, Keen JN, Bouloux PM, Mikhailidis DP, Bruck-dorfer KR, Vanderpump MP, Srai KS 2003 Ghrelin can bind to a species of high density lipoprotein associated with paraxonase. J Biol Chem 278:8877–8880[Abstract/Free Full Text]
  33. Shanado Y, Kometani M, Uchiyama H, Koizumi S, Teno N 2004 Lysophospholipase I identified as a ghrelin deacylation enzyme in rat stomach. Biochem Biophys Res Commun 325:1487–1494[CrossRef][Medline]
  34. Duncan JA, Gilman AG 1998 A cytoplasmic acyl-protein thioesterase that removes plamitate from G protein {alpha} subunits and p21(RAS). J Biol Cehm 273:15830–15837
  35. Chen CY, Imui A, Asakawa A, Fujino K, Kato I, Chen CC, Ueno N, Fujimiya M 2005 Des-acyl ghrelin acts by CRF type 2 receptors to disrupt fasted stomach motility in conscious rats. Gastroenterology 129:8–25[CrossRef][Medline]
  36. Asakawa A, Inui A, Fujimiya M, Sakamaki R, Shinfuku N, Ueta Y, Meguid MM, Kasuga M 2005 Stomach regulates energy balance via acylated ghrelin and desacyl ghrelin. Gut 54:18–24[Abstract/Free Full Text]
  37. Tschöp M, Castaneda TR, Joost HG, Thone-Reineke C, Ortmann S, Klaus S, Hagan MM, Chandler PC, Oswald KD, Benoit SC, Seeley RJ, Kinzig KP, Moran TH, Beck-sickinger AG, Koglin N, Rodgers RJ, Blundell JE, Ishii Y, Beattie AH, Holch P, Allison DB, Raun K, Madsen K, Wulff BS, Stidsen CE, Birringer M, Kreuzer OJ, Schindler M, Arndt K, Rudolf K, Mark M, Deng XY, Whitcomb DC, Halem H, Taylor J, Dong J, Datta R, Culler M, Craney S, Flora D, Smiley D, Heiman ML 2004 Physiology: does gut hormone PYY3–36 decrease food intake in rodents? Nature 430:1–4[Medline]
  38. Halatchev IG, Ellacott KL, Fan W, Cone RD 2004 Peptide YY3–36 inhibits food intake in mice through a melanocortin-4 receptor-independent mechanism. Endocrinology 145:2585–2590[Abstract/Free Full Text]
  39. Jobst EE, Enriori PJ, Cowley MA 2004 The electrophysiology of feeding circuits. Trends Endocrinol Metab 15:488–499[CrossRef][Medline]
  40. Sakurai T 2005 Reverse pharmacology of orexin: from an orphan GPCR to integrative physiology. Regul Pept 126:3–10[CrossRef][Medline]
  41. Yamanaka A, Beuckmann CT, Willie JT, Hara J, Tsujino N, Mieda M, Tominaga M, Yagami K, Sugiyama F, Goto K, Yanagisawa M, Sakurai T 2003 Hypothalamic orexin neurons regulate arousal according to energy balance in mice. Neuron 38:701–713[CrossRef][Medline]
  42. Muccioli G, Papotti M, Locatelli V, Ghigo E, Deghenghi R 2000 Binding of 125I-labeled ghrelin to membranes from human hypothalamus and pituitary gland. J Endocrinol Invest 24:RC7–RC9
  43. Konturek SJ, Konturek JW, Pawlik T, Brzozowski T 2004 Brain-gut axis and its role in the control of food intake. J Physiol Pharmacol 55:137–154[Medline]
  44. Date Y, Murakami N, Toshinai K, Matsukura S, Niijima A, Matsuo H, Kangawa K, Nakazato M 2002 The role of the gastric afferent vagal nerve in ghrelin-induced feeding and growth hormone secretion. Gastroenterology 123:1120–1128[CrossRef][Medline]
  45. Date Y, Toshinai K, Koda S, Miyazato M, Shimbara T, Tsuruta T, Niijima A, Kangawa K, Nakazato M 2005 Peripheral interaction of ghrelin and cholecystokinin on feeding regulation. Endocrinology 146:3518–3525[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
J. Liu, C. E. Prudom, R. Nass, S. S. Pezzoli, M. C. Oliveri, M. L. Johnson, P. Veldhuis, D. A. Gordon, A. D. Howard, D. R. Witcher, et al.
Novel Ghrelin Assays Provide Evidence for Independent Regulation of Ghrelin Acylation and Secretion in Healthy Young Men
J. Clin. Endocrinol. Metab., May 1, 2008; 93(5): 1980 - 1987.
[Abstract] [Full Text] [PDF]

Home page
 Poult. Sci.Home page
J. D. Latshaw
Daily Energy Intake of Broiler Chickens is Altered by Proximate Nutrient Content and Form of the Diet
Poult. Sci., January 1, 2008; 87(1): 89 - 95.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
M. Bossola, S. Giungi, L. Tazza, and G. Luciani
Does desacyl ghrelin contribute to uraemic anorexia?
Nephrol. Dial. Transplant., December 1, 2007; 22(12): 3673 - 3674.
[Full Text] [PDF]

Home page
 Am. J. Clin. Nutr.Home page
T. Ando, Y. Ichimaru, F. Konjiki, M. Shoji, and G. Komaki
Variations in the preproghrelin gene correlate with higher body mass index, fat mass, and body dissatisfaction in young Japanese women
Am. J. Clinical Nutrition, July 1, 2007; 86(1): 25 - 32.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
P. J. D. Delhanty, P. M. van Koetsveld, C. Gauna, B. van de Zande, G. Vitale, L. J. Hofland, and A. J. van der Lely
Ghrelin and its unacylated isoform stimulate the growth of adrenocortical tumor cells via an anti-apoptotic pathway
Am J Physiol Endocrinol Metab, July 1, 2007; 293(1): E302 - E309.
[Abstract] [Full Text] [PDF]

Home page
 J Mol EndocrinolHome page
R. D Kineman, M. D Gahete, and R. M Luque
Identification of a mouse ghrelin gene transcript that contains intron 2 and is regulated in the pituitary and hypothalamus in response to metabolic stress
J. Mol. Endocrinol., May 1, 2007; 38(5): 511 - 521.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
O. Alvarez-Garcia, E. Garcia-Lopez, J. Rodriguez, H. Gil-Pena, I. Molinos, E. Carbajo-Perez, and F. Santos
Administration of ghrelin to young uraemic rats increases food intake transiently, stimulates growth hormone secretion and does not improve longitudinal growth
Nephrol. Dial. Transplant., May 1, 2007; 22(5): 1309 - 1313.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
M. Rauh, M. Groschl, and W. Rascher
Simultaneous Quantification of Ghrelin and Desacyl-Ghrelin by Liquid Chromatography-Tandem Mass Spectrometry in Plasma, Serum, and Cell Supernatants
Clin. Chem., May 1, 2007; 53(5): 902 - 910.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
Y. Sun, J. M. Garcia, and R. G. Smith
Ghrelin and Growth Hormone Secretagogue Receptor Expression in Mice during Aging
Endocrinology, March 1, 2007; 148(3): 1323 - 1329.
[Abstract] [Full Text] [PDF]

Home page
 J EndocrinolHome page
A. S Bang, S. G Soule, T. G Yandle, A M. Richards, and C. J Pemberton
Characterisation of proghrelin peptides in mammalian tissue and plasma
J. Endocrinol., February 1, 2007; 192(2): 313 - 323.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
D. H. St-Pierre, A. D. Karelis, L. Coderre, F. Malita, J. Fontaine, D. Mignault, M. Brochu, J.-P. Bastard, K. Cianflone, E. Doucet, et al.
Association of Acylated and Nonacylated Ghrelin with Insulin Sensitivity in Overweight and Obese Postmenopausal Women
J. Clin. Endocrinol. Metab., January 1, 2007; 92(1): 264 - 269.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
E. Szentirmai, L. Kapas, and J. M. Krueger
Ghrelin microinjection into forebrain sites induces wakefulness and feeding in rats
Am J Physiol Regulatory Integrative Comp Physiol, January 1, 2007; 292(1): R575 - R585.